Amicus Therapeutics, Inc. is a biotechnology-oriented company based in New Jersey. The company’s primary role is to deal with advanced therapies with the sole purpose being to treat and manage a wide range of life-threatening diseases. The company which was founded in the year 2002 brags as having some of the most sophisticated mechanisms that can treat a wide variety of human-oriented genetic diseases, with more concern been paid on the lysosomal storage diseases.
Amicus Therapeutics Inc. mainly produces its products via the Chaperone-Advanced Replacement Therapy (CART). This product development platform has been concentrated more on the development of enzyme replacement therapies which have been used to manage and treat medical conditions such as Pompe disease, Lysosomal Storage Disorders, and Fabry disease. Though Amicus Therapeutics Inc. is believed to have some of the broadest and highly-advanced small molecules for pharmacological uses than any other pharmaceutical company in the industry, it solely lies on contract manufacturing companies since it lacks its own manufacturing plant.
Amicus Therapeutics Inc. acquired its sole competitor Callidus Biopharma and in the process neutralized competition. The purchase saw the company obtain the full proprietary materials owned by Callidus Biopharma as well as the enzyme replacement therapy used in the treatment of Pompe disease.
Amicus Therapeutics Inc. went public under the NASDAQ trading symbol after a previous trading option failed to materialize. During this time, its main funders were Radius Ventures, New Enterprise Associates, and Canaan Partners. In 2008, Amicus Therapeutics Inc. expanded its branches to its second research site based in San Diego California (http://alivenewspaper.com/2017/09/amicus-therapeutics-fabry-disease-treatment/).
Thanks to its positive outlook towards helping the sick, Amicus Therapeutics Inc. has received a substantial amount of money from well-wishers. For instance, in 2010, the company was awarded more than $500,000 grant by The Michael J. Fox Foundation (ForexWizard). The funds were meant to support the numerous studies conducted by the firm in conjunction with David Geffen School of Medicine. Apart from this, the company received more than $210,300 from the Alzheimer’s Drug Discovery Foundation. The grant was to support the pre-clinical research work of Alzheimer in which the company was to conduct with Icahn School of Medicine at Mount Sinai.
More about Amicus Therapeutics on MarketWatch